Perte de poids de 19,3 % à la 48e semaine : présentation lors de l'EASD des données de phase III concernant l'olatorepatide, l'agoniste à double action GLP-1/GIP développé par Hansohƒ

Olatorepatide (HS-20094), a GLP-1 receptor agonist therapy, was featured at the European Association for the Study of Diabetes (EASD) annual congress in Milan, held September 28 to October 2, 2026. The provided article excerpt does not include clinical efficacy, safety, regulatory, or financial data, limiting assessment of its investment significance.